Equities

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)43.39
  • Today's Change-0.68 / -1.54%
  • Shares traded473.99k
  • 1 Year change+50.50%
  • Beta1.2034
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy8
Outperform10
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 15 analysts offering 12 month price targets for Xenon Pharmaceuticals Inc have a median target of 56.50, with a high estimate of 65.00 and a low estimate of 49.00. The median estimate represents a 30.21% increase from the last price of 43.39.
High49.8%65.00
Med30.2%56.50
Low12.9%49.00

Earnings history & estimates in USD

On Nov 12, 2024, Xenon Pharmaceuticals Inc reported 3rd quarter 2024 losses of -0.81 per share. This result was in line with the consensus of the 17 analysts following the company and under-performed last year's 3rd quarter results by 10.96%.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate-3.38%
Xenon Pharmaceuticals Inc reported annual 2023 losses of -2.73 per share on Feb 29, 2024.
Average growth rate-30.01%
More ▼

Revenue history & estimates in USD

Xenon Pharmaceuticals Inc. did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Xenon Pharmaceuticals Inc. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 9.43m.
Average growth rate+44.88%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.